Publicacions en què col·labora amb Vicente Soriano Vázquez (26)

2001

  1. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C

    American Journal of Gastroenterology, Vol. 96, Núm. 1, pp. 179-183

  2. Intensification of antiretroviral therapy

    AIDS Research and Human Retroviruses, Vol. 17, Núm. 6, pp. 499-506

  3. Management of hepatitis C in HIV-infected persons

    Antiviral Research, Vol. 52, Núm. 2, pp. 189-198

  4. Performance of a quadruple combination including nelfinavir plus efavirenz in naive subjects with high baseline viral load and in patients failing protease inhibitor-containing regimens [3]

    Journal of Acquired Immune Deficiency Syndromes

2000

  1. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy

    AIDS, Vol. 14, Núm. 4, pp. 383-386

  2. Efficacy and safety of didanosine and lamivudine both once daily plus indinavir in human immunodeficiency virus-infected patients

    Journal of Human Virology, Vol. 3, Núm. 6, pp. 335-340

  3. Intensificación del tratamiento antirretrovírico

    Revista Clinica Espanola, Vol. 200, Núm. 2, pp. 84-87

  4. Interferon plus ribavirin for chronic hepatitis C in HIV-infected patients

    AIDS, Vol. 14, Núm. 15, pp. 2409-2410

  5. Second Spanish Consensus on the Use of Drug Resistance Testing in Clinical Practice (Madrid, March 2000)

    AIDS Reviews

  6. Terapia antirretrovírica de rescate

    Revista Clinica Espanola, Vol. 200, Núm. 2, pp. 88-94

1999

  1. Diabetes mellitus associated with protease inhibitor use

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 18, Núm. 9, pp. 675-677

  2. El virus de la hepatitis C: tras los pasos del virus de la inmunodeficiencia humana.

    Revista clínica española

  3. Hepatitis C and HTV infection: Biological, clinical, and therapeutic implications

    Journal of Hepatology, Supplement, Vol. 31, Núm. 1, pp. 119-123

  4. Higher antiviral activity of antiretroviral regimens including protease inhibitors [5]

    AIDS

  5. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users

    European Journal of Epidemiology, Vol. 15, Núm. 1, pp. 1-4

  6. Incidence of rash and discontinuation of nevirapine using two different escalating initial doses.

    AIDS (London, England)

  7. Introduction of HIV drug-resistance testing in clinical practice

    AIDS, Vol. 13, Núm. 9, pp. 1007-1014

  8. Management of chronic hepatitis C in HIV-infected patients

    AIDS, Vol. 13, Núm. 5, pp. 539-546

  9. Usefulness of genotypic analysis of resistance to nucleoside analogues in the clinical setting

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 18, Núm. 6, pp. 448-449

  10. What dual protease inhibitor combination for salvage therapies? [8]

    AIDS